Chris Ashton, PhD
Chris Ashton currently serves as an Advisor to Oxford Science Enterprises. He joined in December 2019 as a seasoned biotech entrepreneur with more than 35 years’ experience in the biotechnology industry. Chris has considerable expertise in leading and growing early stage companies through their transition to mid-stage clinical development organizations. He has extensive international transactional experience including fundraising, licensing, and M&A activity. Chris was formerly a Partner at Syncona and was also the founding CEO of Achilles Therapeutics. Prior to that he was CEO of Argenta Discovery (acquired by Galapagos) and Pulmagen Therapeutics. Chris has a PhD from UMIST and carried out post-doctoral research at MIT.